替吉奥单药治疗老年晚期非小细胞肺癌疗效及毒性反应观察

摘要

Objective To observe the efficacy and toxicity of S -1 monotherapy in elderly patients with advanced non -small lung cancer (NSCLC).Methods Fifty-six patients aged 70 or over with stage IIIb-IV NSCLC were enrolled.S-1 was given orally twice a day according to body surface area on days 1 to 14 for 21-day cycle, the evaluation of efficacy and toxicity were performed on all patients after 2 cycles.Results For all 56 patients, CR 0, PR 15, SD 29 and PD 23 were observed.The objective response rate (ORR) and the disease control rate (DCR) were 26.8% and 78.6%,respectively.The 1-year survival rate was 30.9%, with a medi-an survival of 10.0 months.The myelotoxicity and gastrointestinal toxicity were major side effects .The major toxicity could be tolerated by the patients.Conclusions S-1 monotherapy is an effective chemotherapy for advanced NSCLC in elderly patients with moderate side effects and safety in clinical practice .%目的：观察替吉奥单药治疗老年晚期非小细胞肺癌（NSCLC）的疗效和毒性反应。方法≥70岁的 IIIb 期和IV 期老年 NSCLC 患者56例，根据患者体表面积接受替吉奥胶囊单药化疗，连续服用14、21d 为一周期，每例至少治疗2个周期后评价疗效。结果56例患者完全缓解（CR）0例，部分缓解（PR）15例，病灶稳定（SD）29例，病灶进展（PD）12例，客观缓解率为26．8％，疾病控制率为78．6％。中位生存时间为10．0个月，1年生存率为30．9％。化疗主要不良反应为骨髓抑制及消化道反应，但反应较轻，患者均能接受。结论替吉奥治疗老年晚期非小细胞肺癌安全性高，疗效肯定，毒副作用比较轻，是一种安全可靠的治疗选择。